Growth Factor Injection Composition for Connective Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments for connective tissue injuries, particularly those resulting from trauma, as existing treatments often fail to adequately address swelling and promote healing in connective tissues such as tendons, fascia, and joint capsules.
Innovation Solution
A therapeutic composition comprising transforming growth factor beta 1 (TGF-β1) and/or transforming growth factor beta 2 (TGF-β2), connective tissue growth factor (CTGF), and pharmaceutically acceptable excipients or secondary agents, administered via injection near the injured connective tissue to stimulate repair and reduce swelling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for connective tissue injuries, then treatment simplicity is maintained, but healing effectiveness and swelling reduction are insufficient
Solution Approach 1:
The patent employs a composite therapeutic composition containing multiple growth factors (TGF-β1, TGF-β2, CTGF) combined with pharmaceutically acceptable excipients. This composite approach synergistically combines different biological agents to simultaneously promote collagen synthesis, tissue repair, and swelling reduction, thereby resolving the contradiction between healing effectiveness and treatment simplicity by providing a multi-functional formulation that addresses multiple aspects of connective tissue injury repair in a single injection.
Solution Approach 2:
The patent utilizes specific concentration ranges and ratios of growth factors (TGF-β1, TGF-β2, CTGF) to optimize therapeutic effects. By carefully controlling the parameters of growth factor concentrations and their combinations, the formulation achieves enhanced healing effectiveness while maintaining manageable treatment complexity through standardized pharmaceutical formulations.
2Reliability
If growth factor therapy is administered to promote collagen synthesis, then tissue repair is enhanced, but treatment cost increases
Solution Approach 1:
The patent employs localized injection of the growth factor composition directly at or near the injured connective tissue site. This partial action approach concentrates the therapeutic effect precisely where needed, promoting collagen synthesis and tissue repair at the injury location without requiring systemic administration of large quantities of growth factors, thereby reducing overall substance quantity requirements while maintaining high tissue repair effectiveness.
3Reliability
If multiple excipients are included in the therapeutic composition, then therapeutic efficacy is enhanced, but formulation complexity increases
Solution Approach 1:
The patent incorporates pharmaceutically acceptable excipients that serve multiple functions: maintaining growth factor stability, controlling release kinetics, reducing inflammation, and providing analgesic effects. This multi-functionality approach allows a single excipient to address multiple therapeutic needs, enhancing overall therapeutic efficacy while minimizing formulation complexity by avoiding the need for separate components for each function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition promotes collagen synthesis and tissue repair, reducing swelling and pain, thereby enhancing the healing process in connective tissues like tendons, fascia, and joint capsules.
Implementation Method 1
the therapeutic composition comprises transforming growth factor beta 1 (TGF-β1) and/or transforming growth factor beta 2 (TGF-β2)
Implementation Method 2
connective tissue growth factor (CTGF)
Data Source
AI summary
This disclosure relates to treating a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) and/or transforming growth factor β 2 (TGF-β2), connective tissue growth factor (CTGF), and a pharmaceutically acceptable excipient or a secondary agent.